Shanghai Haohai Biological Technology Co Ltd 2020 SR
The report highlights Shanghai Haohai Biological Technology's ESG performance for 2020, focusing on its strategic expansion in ophthalmology and medical aesthetics. Key achievements include the acquisition of Hangzhou Aijinglun and the launch of the Hyalumatrix HA Dermal Filler. The company increased its R&D investment to 9.55% of operating revenue and obtained 32 authorized patents. Environmentally, the group implemented low-nitrogen renovations for boilers and optimized wastewater treatment processes. Socially, it contributed to COVID-19 relief efforts and launched the Bright Eyes for 100 People public welfare action.
Company: Shanghai Haohai Biological Technology Co Ltd
Sector: Manufacturing
Country: China
Year: 2020
Type: SR
Pages: 40
Back to company
Shanghai Haohai Biological Technology Co Ltd
ESG Report
The report highlights Shanghai Haohai Biological Technology's ESG performance for 2020, focusing on its strategic expansion in ophthalmology and medical aesthetics. Key achievements include the acquisition of Hangzhou Aijinglun and the launch of the Hyalumatrix HA Dermal Filler. The company increased its R&D investment to 9.55% of operating revenue and obtained 32 authorized patents. Environmentally, the group implemented low-nitrogen renovations for boilers and optimized wastewater treatment processes. Socially, it contributed to COVID-19 relief efforts and launched the Bright Eyes for 100 People public welfare action.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Published
Apr 23, 2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees